Back to News
Market Impact: 0.2
Tenax's Phase 3 Study For TNX-103 Fails To Meet Primary Endpoint; Shows Success In Other Measures
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsAnalyst Insights
Tenax Therapeutics (TENX) announced clinical results from its Phase 3 LEVEL trial for TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. The article provides that results were disclosed but does not include key efficacy/safety figures in the provided text, limiting conviction on expected upside or downside.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
TENX0.35
More News
- Bending Spoons Stock Soars on Berkshire’s Increased Stake
- Travis Kelce joined an activist group pushing Six Flags to consider a sale. The ‘Final Destination’-style death of a patron poured gas on the fire
- ‘The biggest financial institutions are not above the law’: Bessent hits BofA with $1.2 billion fine for money laundering—the third-largest in history
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- We bought SpaceX at $121. Here's why we're buying more at higher prices
- Inside the Making of ‘Grand Theft Auto VI’
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What Exactly Does Post-Training in LLMs and Finance-Focused AI Actually Mean for Asset Managers?
- What Is a Financial Ontology?